Spherix (Formerly Known As Biospherics Incorporated)
One Rockefeller Plaza, 11th Floor
New York
New York
20705
United States
Tel: 703-992-9325
Website: http://www.spherix.com
Email: info@spherix.com
203 articles about Spherix (Formerly Known As Biospherics Incorporated)
-
Spherix Completes Name Change to AIkido Pharma Inc.
3/13/2020
Spherix Incorporated today announced it has completed its name change to AIkido Pharma Inc. and now trades under the ticker "AIKI". The name change reflects company's increased focus on the use of Artificial Intelligence and Machine Learning (AI and ML) in the drug developm
-
Spherix Announces Closing of $5.75 Million Registered Direct Offering Priced At-the-Market
3/10/2020
Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, announced today the closing of its previously announced registered direct offering with several institutional investors of 2,090,909 shares of its common stock at a purchase price of $2.75 per share,
-
Shareholder Update on Treatment for Coronavirus Optioned by Spherix
3/10/2020
Spherix Incorporated provided an update on the recently announced treatment for Coronavirus technology optioned by the Company.
-
Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market
3/9/2020
Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,090,909 shares of Spherix's common stock, at a purchase
-
Spherix Incorporated Changing Name to AIkido Pharma Inc. to Reflect Increased Focus on Artificial Intelligence and Machine Learning in Drug Development
3/5/2020
Spherix Incorporated (Nasdaq: SPEX) ("Spherix" or the "Company") today announced that on March 13, 2020 , the Company will officially change its name to AIkido Pharma Inc. ("AIkido"). Effective at the start of trading on March 13, 2020 , the Company's shares will trade on the Nasdaq Capital Market under the new name and the new stock
-
Spherix Moves Dividend Record Date to Friday, March 6, 2020
3/4/2020
Spherix Incorporated (Nasdaq: SPEX) announced that, in light of the expected closing of its public offering tomorrow, March 5, 2020 , the record date with respect to the Hoth dividend has been moved to Friday, March 6, 2020 , so that its new shareholders may participate in the Hoth dividend.
-
Spherix Executes Machine Learning Scientific Research Agreement
3/3/2020
Spherix Incorporated (Nasdaq: SPEX) today announced it has executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center with the goal of using machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.
-
Spherix Announces Pricing of $7.5 Million Public Offering
3/3/2020
Spherix Incorporated announced that it has priced a public offering of an aggregate of 7,142,858 shares of common stock of the Company and warrants to purchase up to 7,142,858 shares of common stock.
-
Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference
2/25/2020
NEW YORK , Feb. 25, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced its attendance at the AI & ML Drug Discovery Summit . The AI-ML in Drug Development Summit is the only conference to bring together industry leaders, technology experts and academics focused on augmenting the R&D processes through the use of Artificial Intelligence and Machine
-
Spherix Issues Letter to Shareholders - Feb. 14, 2020
2/14/2020
Spherix Incorporated, a technology development company committed to the fostering of innovative ideas, issued a letter to shareholders
-
Spherix Launches Newly Redesigned Website
1/21/2020
Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website (www.spherix.com) to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics
-
Spherix Issues Update to Shareholders - Oct. 21, 2019
10/21/2019
Spherix Incorporated President and CEO, Anthony Hayes, released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution.
-
Spherix Highlights ValuEngine Upgrade to 'Buy' Rating
10/17/2019
Spherix Incorporated today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note issued to investors by ValuEngine Inc.
-
Spherix Sets Record Date for Dividend Distribution
10/11/2019
Spherix Incorporated (Nasdaq: SPEX) today announced that on October 2, 2019, the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 100,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix.
-
Spherix Issues Update to Shareholders
10/1/2019
Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders.
-
Spherix Issues Update to Shareholders Regarding Planned Dividend Distribution
9/25/2019
Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution.
-
University of Maryland, Baltimore Grants Spherix Exclusive Option to License Anthrax Based Ovarian Cancer Drug PrAg-PAS
9/17/2019
Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Maryland, Baltimore (UMB) related to its anticancer drug designated PrAg-PAS, a novel protein drug designed by re-engineering the anthrax toxin delivery mechanism so that any one of a number of anticancer drug payloads may be specifically transported into ovarian cancer cells.
-
Spherix Announces Results of Special Meeting of Shareholders
9/9/2019
Spherix Incorporated (Nasdaq: SPEX) today announced results from the Special Meeting of Shareholders held on September 5th (the "Meeting").
-
Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting
8/19/2019
Spherix Incorporated, (NASDAQ: SPEX) a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders:
-
Spherix Inc. (NasdaqCM: SPEX) Trading Below Book Value; Diversified Asset Base Adds Value
6/11/2019
Spherix's investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%. The recently announced asset-purchase agreement of CBM BioPharma extends pipeline promise.